For: | Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017; 9(7): 281-292 [PMID: 28808501 DOI: 10.4251/wjgo.v9.i7.281] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v9/i7/281.htm |
Number | Citing Articles |
1 |
Sai Ping Lau, Freek R van ’t Land, Sjoerd H van der Burg, Marjolein Y V Homs, Martijn P Lolkema, Joachim G J V Aerts, Casper H J van Eijck. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial). BMJ Open 2022; 12(6): e060431 doi: 10.1136/bmjopen-2021-060431
|
2 |
Benjamin Fook Lun Lai, Rick Xing Ze Lu, Yangshuo Hu, Locke Davenport Huyer, Wenkun Dou, Erika Yan Wang, Nikolina Radulovich, Ming Sound Tsao, Yu Sun, Milica Radisic. Recapitulating Pancreatic Tumor Microenvironment through Synergistic Use of Patient Organoids and Organ‐on‐a‐Chip Vasculature. Advanced Functional Materials 2020; 30(48) doi: 10.1002/adfm.202000545
|
3 |
Susann Theile, Julia Sidenius Johansen, Dorte Lisbet Nielsen, Benny Vittrup Jensen, Carsten Palnæs Hansen, Jane Preuss Hasselby, Sverrir Vídalín Eiríksson, Inna Markovna Chen. A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). Pharmaceutics 2022; 14(3): 509 doi: 10.3390/pharmaceutics14030509
|
4 |
Takamitsu Sasaki, Rina Fujiwara‐Tani, Shingo Kishi, Shiori Mori, Yi Luo, Hitoshi Ohmori, Isao Kawahara, Kei Goto, Yukiko Nishiguchi, Takuya Mori, Masayuki Sho, Masuo Kondo, Hiroki Kuniyasu. Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas. Cancer Medicine 2019; 8(15): 6700 doi: 10.1002/cam4.2547
|
5 |
Lirong Ma, Xuanlin Yang, Xiuzhong Yao, Weiyu Weng. Solubilization of Hexyl Aminolevulinate by Surfactants for Tumor Fluorescence Detection. Photochemistry and Photobiology 2020; 96(5): 1088 doi: 10.1111/php.13252
|
6 |
Devon J. Boyne, Darren R. Brenner, Alind Gupta, Eric Mackay, Paul Arora, Radek Wasiak, Winson Y Cheung, Miguel A. Hernán. Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Annals of Epidemiology 2023; 78: 28 doi: 10.1016/j.annepidem.2022.12.005
|
7 |
Yi-Lun Chen, Chiao-Ling Tsai, Jason Chia-Hsien Cheng, Chun-Wei Wang, Shih-Hung Yang, Yu-Wen Tien, Sung-Hsin Kuo. Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.730646
|
8 |
Vaibhav Sahai, Paul J. Catalano, Mark M. Zalupski, Sam Joseph Lubner, Mark R. Menge, Halla Sayed Nimeiri, Hidayatullah G. Munshi, Al Bowen Benson, Peter J. O’Dwyer. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma. JAMA Oncology 2018; 4(12): 1707 doi: 10.1001/jamaoncol.2018.3277
|
9 |
Renata Talar-Wojnarowska, Małgorzata Woźniak, Anna Borkowska, Katarzyna Cypryk, Marek Olakowski, Ewa Małecka-Panas. Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma. Medicina 2020; 56(12): 677 doi: 10.3390/medicina56120677
|
10 |
Elena Gabriela Chiorean, Winson Y. Cheung, Guido Giordano, George Kim, Salah-Eddin Al-Batran. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Therapeutic Advances in Medical Oncology 2019; 11 doi: 10.1177/1758835919850367
|
11 |
Fleur van der Sijde, Eveline E. Vietsch, Dana A. M. Mustafa, Marc G. Besselink, Bas Groot Koerkamp, Casper H. J. van Eijck. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers 2019; 11(1): 93 doi: 10.3390/cancers11010093
|
12 |
Michele Reni, Guido Giordano, Marco Audisio, Giulia Orsi, Marina Macchini, Stefania Maria Gobba, Ilario Rapposelli, Antonio Lucenti, Giovanna Luchena, Luca Faloppi, Fable Zustovich, Vincenzo Ricci, Massimiliano Cergnul, Vincenzo Formica, Letizia Procaccio, Valeria Baccolini, Assunta Briccolani, Stefano Cascinu, Umberto Peretti. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. Digestive and Liver Disease 2024; doi: 10.1016/j.dld.2024.06.025
|
13 |
Fleur van der Sijde, Dana A.M. Mustafa, Eveline E. Vietsch, Peter D. Katsikis, Casper H. J. van Eijck. Circulating Immunological Biomarkers. Pancreas 2021; 50(7): 933 doi: 10.1097/MPA.0000000000001862
|
14 |
Fleur van der Sijde, Jacob L. van Dam, Bas Groot Koerkamp, Brigitte C. M. Haberkorn, Marjolein Y. V. Homs, Daniëlle Mathijssen, Marc G. Besselink, Johanna W. Wilmink, Casper H. J. van Eijck, Yingming Sun. Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/8549487
|
15 |
Yves Rinaldi, Anne-Laure Pointet, Faiza Khemissa Akouz, Karine Le Malicot, Bidaut Wahiba, Samy Louafi, Alain Gratet, Laurent Miglianico, Hortense Laharie, Karine Bouhier Leporrier, Anne Thirot Bidault, Patrick Texereau, Romain Coriat, Eric Terrebonne, Marie-Claude Gouttebel, David Malka, Jean-Baptiste Bachet, Côme Lepage, Julien Taieb, Cécile Julien, Nicolas Barriere, Julie Gigout, Simon Pernot, Céline Lepere, Aziz Zaanan, Géraldine Perkins, Raymond Despax, Jérôme Chamois, Xavier Artignan, Pauline Regnault, Benoît Dupont, Maxime Lesouef, Leila Bengrine Lefevre, Julie Vincent, François Ghiringhelli, Mme E. Barbier, Morgan Andre, Johann Dreanic, Catherine Brezault-Bonnet, Valérie Boige, Antoine Holllebecque, Bruno Valenza, Gildas Phelip, Philippe Dominici, Marion Chauvenet, Frederick Moryoussef, Pierre-Luc Etienne, Dominique Besson, Mathilde Martinez, Pamela Biondiani, Benoît Avisse, Marie-Pierre Galais, Aurélie Parzy, Salvatore Caruso, Jean-François Codoul, Iulia Pripon, Mustapha Atlassi, Oana Cojocarasu, Etienne Suc, Ahmed Bedjaoui, Philippe Houyau, Yann Berge, Dany Gargot, Vincent Bourgeois, Pierre-Emmanuel Henneresse, Sandrine Lavau denes, Valérie Lebrun Lyat, Dominique Genet, Jean Martin, Pr Pierre Michel, David Sefrioui, Anne Escande, Louis-Marie Dourthe. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). European Journal of Cancer 2020; 136: 25 doi: 10.1016/j.ejca.2020.05.018
|
16 |
Siqi Guo, Niculina I. Burcus, James Hornef, Yu Jing, Chunqi Jiang, Richard Heller, Stephen J. Beebe. Nano-Pulse Stimulation for the Treatment of Pancreatic Cancer and the Changes in Immune Profile. Cancers 2018; 10(7): 217 doi: 10.3390/cancers10070217
|
17 |
Zaizhu Zhang, Nina Zhou, Xiaoyi Guo, Nan Li, Hua Zhu, Zhi Yang. Pretherapeutic Assessment of Pancreatic Cancer: Comparison of FDG PET/CT Plus Delayed PET/MR and Contrast-Enhanced CT/MR. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.790462
|
18 |
Chuhua Xin, Xiuzhong Yao, Bin Du, Weiyu Yang, Liuguo Wang, Lirong Ma, Weiyu Weng. Stearic Acid-Grafted Chitooligosaccharide Nanomicelle System with Biocleavable Gadolinium Chelates as a Multifunctional Agent for Tumor Imaging and Drug Delivery. Pharmaceutical Research 2019; 36(1) doi: 10.1007/s11095-018-2530-2
|
19 |
J.W. Lee, S.M. Lee, Y.A. Chung. Prognostic value of CT attenuation and FDG uptake of adipose tissue in patients with pancreatic adenocarcinoma. Clinical Radiology 2018; 73(12): 1056.e1 doi: 10.1016/j.crad.2018.07.094
|
20 |
Mohammad Yasrab, Sameer Thakker, Michael J. Wright, Taha Ahmed, Jin He, Christopher L. Wolfgang, Linda C. Chu, Matthew J. Weiss, Satomi Kawamoto, Pamela T. Johnson, Elliot K. Fishman, Ammar A. Javed. Factors associated with radiological misstaging of pancreatic ductal adenocarcinoma: A retrospective observational study. Current Problems in Diagnostic Radiology 2024; 53(4): 458 doi: 10.1067/j.cpradiol.2024.03.001
|
21 |
Jeong Won Lee, Sang-Heum Park, Hyein Ahn, Sang Mi Lee, Su Jin Jang. Predicting Survival in Patients with Pancreatic Cancer by Integrating Bone Marrow FDG Uptake and Radiomic Features of Primary Tumor in PET/CT. Cancers 2021; 13(14): 3563 doi: 10.3390/cancers13143563
|
22 |
Jeong Won Lee, Joo Hyun O, Miyoung Choi, Joon Young Choi. Impact of F-18 Fluorodeoxyglucose PET/CT and PET/MRI on Initial Staging and Changes in Management of Pancreatic Ductal Adenocarcinoma: A Systemic Review and Meta-Analysis. Diagnostics 2020; 10(11): 952 doi: 10.3390/diagnostics10110952
|
23 |
Sumit Sahni, Advait R. Pandya, William J. Hadden, Christopher B. Nahm, Sarah Maloney, Victoria Cook, James A. Toft, Lorna Wilkinson‐White, Anthony J. Gill, Jaswinder S. Samra, Anthony Dona, Anubhav Mittal. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. International Journal of Cancer 2021; 148(6): 1508 doi: 10.1002/ijc.33368
|
24 |
Norihiko Sasaki, Kazumi Hirano, Yuuki Shichi, Fujiya Gomi, Hisashi Yoshimura, Akira Matsushita, Masashi Toyoda, Toshiyuki Ishiwata. Gp130-Mediated STAT3 Activation Contributes to the Aggressiveness of Pancreatic Cancer through H19 Long Non-Coding RNA Expression. Cancers 2022; 14(9): 2055 doi: 10.3390/cancers14092055
|
25 |
Adriana Harbuzariu, Gabriela Oprea-Ilies, Ruben R. Gonzalez-Perez. Advances in Pancreatic Cancer. 2018; doi: 10.5772/intechopen.76400
|
26 |
Daniel S.K. Liu, Mireia Mato Prado, Elisa Giovannetti, Long R. Jiao, Jonathan Krell, Adam E. Frampton. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?. Expert Review of Molecular Diagnostics 2019; 19(7): 553 doi: 10.1080/14737159.2019.1622414
|